Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) EPS (Basic) (2018 - 2025)

BioNexus Gene Lab's EPS (Basic) history spans 7 years, with the latest figure at -$0.08 for Q3 2024.

  • For Q3 2024, EPS (Basic) rose 51.32% year-over-year to -$0.08; the TTM value through Sep 2024 reached -$0.08, up 51.32%, while the annual FY2023 figure was -$0.17, 849.41% down from the prior year.
  • EPS (Basic) for Q3 2024 was -$0.08 at BioNexus Gene Lab, down from $0.01 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.02 in Q4 2023 and bottomed at -$0.16 in Q3 2023.
  • The 5-year median for EPS (Basic) is $0.0 (2022), against an average of -$0.01.
  • The largest annual shift saw EPS (Basic) soared 1188.28% in 2020 before it plummeted 2809.22% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at $0.01 in 2020, then tumbled by 94.36% to $0.0 in 2021, then crashed by 636.32% to -$0.0 in 2022, then soared by 709.49% to $0.02 in 2023, then tumbled by 441.96% to -$0.08 in 2024.
  • Per Business Quant, the three most recent readings for BGLC's EPS (Basic) are -$0.08 (Q3 2024), $0.01 (Q2 2024), and -$0.01 (Q1 2024).